[go: up one dir, main page]

TR201906285T4 - İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi. - Google Patents

İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi. Download PDF

Info

Publication number
TR201906285T4
TR201906285T4 TR2019/06285T TR201906285T TR201906285T4 TR 201906285 T4 TR201906285 T4 TR 201906285T4 TR 2019/06285 T TR2019/06285 T TR 2019/06285T TR 201906285 T TR201906285 T TR 201906285T TR 201906285 T4 TR201906285 T4 TR 201906285T4
Authority
TR
Turkey
Prior art keywords
tumor cells
rescue
removal
blood
autologous blood
Prior art date
Application number
TR2019/06285T
Other languages
English (en)
Inventor
Lindhofer Horst
Stroehlein Michael
Heiss Markus
Original Assignee
Lindis Blood Care Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lindis Blood Care Gmbh filed Critical Lindis Blood Care Gmbh
Publication of TR201906285T4 publication Critical patent/TR201906285T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Buluş, intraoperatif olarak toplanan kan kurtarımından tümör hücrelerinin giderilmesine yönelik ex vivo gerçekleştirilen bir yöntem ile, söz konusu ex vivo yöntemde kullanılması için antikorları taklit eden antikolar ve iskele proteinleri ile, bu şekilde elde edilen saflaştırılmış kan kurtarımını takiben intraoperatif olarak toplanan kan kurtarımından tümör hücrelerinin veya söz konusu yöntem ile saflaştırılan eritrositlerin konsantrelerinin giderilmesine yönelik söz konusu ex vivo yöntemin söz konusu intraoperatif olarak toplanan kanın elde edildiği bir hasta için kullanımı ile, bunun yanı sıra her ikisinin söz konusu hastaya reinfüzyona yönelik yöntem ile elde edilebildiği kan kurtarımı veya eritrositlerin bir konsantrasyonu ile ilgilidir.
TR2019/06285T 2011-10-04 2012-10-04 İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi. TR201906285T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11183851.2A EP2578230A1 (en) 2011-10-04 2011-10-04 Removal of Tumor Cells from Intraoperative Autologous Blood Salvage

Publications (1)

Publication Number Publication Date
TR201906285T4 true TR201906285T4 (tr) 2019-05-21

Family

ID=46968231

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/06285T TR201906285T4 (tr) 2011-10-04 2012-10-04 İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi.

Country Status (8)

Country Link
US (1) US9605242B2 (tr)
EP (2) EP2578230A1 (tr)
DK (1) DK2903640T3 (tr)
ES (1) ES2727630T3 (tr)
PL (1) PL2903640T3 (tr)
PT (1) PT2903640T (tr)
TR (1) TR201906285T4 (tr)
WO (1) WO2013050445A1 (tr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874821B1 (de) 2005-04-26 2013-04-17 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US9789485B2 (en) 2012-09-21 2017-10-17 Massachusetts Institute Of Technology Micro-fluidic device and uses thereof
EP2904016B1 (en) 2012-10-08 2018-11-14 Roche Glycart AG Fc-free antibodies comprising two fab-fragments and methods of use
HK1211299A1 (en) * 2013-02-26 2016-05-20 罗切格利卡特公司 Bispecific t cell activating antigen binding molecules
EP2961771B1 (en) 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
MX2015010350A (es) 2013-02-26 2015-10-29 Roche Glycart Ag Moleculas de union a antigeno biespecificas que activan la celula t.
EP3192812B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
PE20170263A1 (es) 2014-08-04 2017-03-30 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
BR112017004802A2 (pt) 2014-09-12 2017-12-12 Genentech Inc anticorpos anti-cll-1 e imunoconjugados
US10806845B2 (en) 2014-09-17 2020-10-20 Massachusetts Institute Of Technology System and method for inertial focusing microfiltration for intra-operative blood salvage autotransfusion
CA2968162A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
DK3221356T3 (da) 2014-11-20 2020-11-02 Hoffmann La Roche T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
LT3789402T (lt) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
EP3310378B1 (en) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
HUE063270T2 (hu) 2015-06-16 2024-01-28 Hoffmann La Roche Az FcRH5 elleni humanizált és affinitásérett antitestek és alkalmazási eljárások
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN107849137B (zh) 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
PL3433280T3 (pl) 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
PL3519437T3 (pl) 2016-09-30 2022-01-17 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste przeciwko p95HER2
CA3042435A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP2020515532A (ja) * 2017-03-29 2020-05-28 グリコトープ ゲーエムベーハー Ｍｕｃ１およびｃｄ３に結合する多重特異的抗体構築物
CA3086405A1 (en) 2018-01-05 2019-07-11 Path Ex, Inc. Device for the capture and removal of disease material from fluids
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
US11608376B2 (en) * 2018-12-21 2023-03-21 Hoffmann-La Roche Inc. Tumor-targeted agonistic CD28 antigen binding molecules
CN114364415B (zh) * 2019-07-18 2026-01-09 林迪斯血液护理有限责任公司 用三功能抗体清除术中自体血液回收中的肿瘤细胞
IL298402A (en) 2020-06-19 2023-01-01 Hoffmann La Roche Antibodies that bind to CD3 and CD19
EP3991796A1 (en) 2020-10-27 2022-05-04 Lindis Blood Care GmbH An ex vivo method for removal of tumor cells from intra-operatively salvaged blood
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US12516118B2 (en) 2020-11-04 2026-01-06 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
BR112023023775A2 (pt) 2021-05-14 2024-02-20 Genentech Inc Métodos para tratar um indivíduo com um distúrbio proliferativo de células positivas para cd20 e para tratar uma população de indivíduos com um distúrbio proliferativo de células positivas para cd20

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
ES2169299T3 (es) 1996-09-03 2002-07-01 Gsf Forschungszentrum Umwelt Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US8865172B2 (en) * 2000-05-08 2014-10-21 Advanced Extravascular Systems, Inc. Method for reducing the number of unwanted molecules in bodily fluids
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
EP2033657A1 (de) * 2007-09-04 2009-03-11 Trion Pharma Gmbh Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination

Also Published As

Publication number Publication date
EP2903640B8 (en) 2019-04-17
EP2903640B1 (en) 2019-02-27
EP2903640A1 (en) 2015-08-12
WO2013050445A1 (en) 2013-04-11
US9605242B2 (en) 2017-03-28
DK2903640T3 (en) 2019-05-06
US20140369985A1 (en) 2014-12-18
EP2578230A1 (en) 2013-04-10
ES2727630T3 (es) 2019-10-17
PT2903640T (pt) 2019-05-31
PL2903640T3 (pl) 2020-01-31

Similar Documents

Publication Publication Date Title
TR201906285T4 (tr) İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi.
MX2012011197A (es) Metodos, sistemas y dispositivos para separar celulas tumorales.
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA201790508A1 (ru) Мембраны гемодиализа и гемофильтрации на основе двумерного мембранного материала и способы их применения
EA201590247A1 (ru) Антитела к siglec-15
MA52909A (fr) Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
CY1119877T1 (el) Χορηγουμενο απο το στομα προσροφητικο που περιεχει ινα ενεργου ανθρακα
EP2813253A3 (en) Methods for treating a suspension of mononuclear cells to facilitate extracorporeal photopheresis
EA201591501A1 (ru) Терапевтические средства на основе csf-1
EA201391019A1 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
WO2012162165A3 (en) Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
EP2882850A4 (en) SYSTEM AND METHOD FOR THE PRODUCTION OF STRAIN CELLS FROM FAT TISSUE
CY1122185T1 (el) Ιατρικη χρηση ενωσεων αρτεμισινινης και αγωνιστων γεφυρινης
BR112015021189A2 (pt) métodos de banco de células de alta densidade
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
CY1116318T1 (el) Μακροκυκλικη ενωση και μεθοδοι για την παραγωγη της
EA201400274A1 (ru) Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека
EP2903632A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
EP2663193A4 (en) CARBON MONOXIDE SOLUTION FOR TREATMENT OF DISEASE, IN PARTICULAR DREPANOCYTOSIS
EA201691563A1 (ru) Сухой кислотный концентрат в гранулированной форме